Clin Mol Hepatol.
2022 Apr;28(2):181-182. 10.3350/cmh.2022.0028.
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
- Affiliations
-
- 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
- 2Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan
- 3Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
- KMID: 2528247
- DOI: http://doi.org/10.3350/cmh.2022.0028
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
- Bone Scintigraphy and Tenofovir-Induced Osteomalacia in Chronic Hepatitis B
- Unmet need in chronic hepatitis B management
- Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
- Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
